Heart Failure Patients Registry

Mean age

At baseline of this study

Time frame: Baseline

Proportion of men and women

At baseline of this study

Time frame: Baseline

Proportion of patients with negative lifestyle factors

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different etiology of CHF

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with a history of HF comorbidities and conditions of special interest

At baseline of this study

Time frame: Baseline

Mean duration of comorbidities listed in previous paragraph (p. 5) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different chronic comorbidities

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with history of COVID-19

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with vaccination

At baseline of this study

Time frame: Baseline

Proportion of patients with different types of HF based on LVEF

At baseline of this study

Time frame: Baseline

Proportion of patients with T2DM comorbid with different types of HF based on LVEF

At baseline of this study

Time frame: Baseline

Mean HbA1c (for patients with T2DM) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF);

At baseline of this study

Time frame: Baseline

Proportions of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different levels of HbA1c (for patients with T2DM)

At baseline of this study

Time frame: Baseline

Mean BMI (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different BMI levels

The BMI will be calculated using a formula based on the patient's anthropometric data collected at visit q (height measured in meters and body weight measured in kilograms). BMI (kg / m2) is calculated using the formula: BMI = weight (kg) / (height2 (m2))

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of CHF according to NYHA classification based on patient symptoms of HF

At baseline of this study

Time frame: Baseline

Mean NT-proBNP level (or BNP)

NT-proBNP is measured in pg / mL. At baseline of this study

Time frame: Baseline

Mean heart rate (HR) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF);

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different functional classes of HF according to SHOKS level

1. Functional Class I - ≤3 points; 2. Functional Class II - from 4 to 6 points; 3. Functional Class III - from 7 to 9 points; 4. Functional Class IV - more than 9 points; At baseline of this study.

Time frame: Baseline

Mean SBP (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

SBP - Systolic blood pressure. At baseline of this study.

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with SBP

1. \<90 mm Hg; 2. 90-99 mm Hg; 3. 100-109 mm Hg; 4. 110-119 mm Hg; 5. 120-139 mm Hg; 6. 140-159 mm Hg; 7. ≥160 mm Hg; At baseline of this study

Time frame: Baseline

Mean Diastolic blood pressure (DBP) (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with DBP

1. \<90 mm Hg; 2. ≥90 mm Hg; At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with concomitant CKD of different stages

eGFR = 141 x min(SCr/κ, 1)\^α x max(SCr/κ, 1)\^-1.209 x 0.993\^Age x 1.018 \[if female\] x 1.159 \[if Black\], where eGFR (estimated glomerular filtration rate) = mL/min/1.73 m\^2, SCr (standardized serum creatinine) = mg/dL, κ = 0.7 (females) or 0.9 (males), α = -0.329 (females) or -0.411 (males), min = indicates the minimum of SCr/κ or 1, max = indicates the maximum of SCr/κ or 1, age = years. At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CKD and different levels of albumin-to-creatinine ratio in a spot urine sample

1. \<30 mg/g; 2. 30-300 mg/g; 3. \>300 mg/g; At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hyperkalemia (K+ level >5,5 mmol/L)

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample, in subgroups of patients with HFrEF, HFmEF and HFpEF, in sub-subgroups of patients with CKD and without CKD) with concomitant hypokalemia (K+ level <3,5 mmol/L)

At baseline of this study

Time frame: Baseline

Mean LVEF (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Mean K+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Mean Na+ level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Mean hemoglobin level (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF)

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different rhythm

1. Sinus rhythm; 2. AF / AFl; 3. Pacemaker rhythm; At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with different QRS duration

1. \<130 ms; 2. 130-150 ms; 3. \>150 ms; At baseline of this study

Time frame: Baseline

Proportion of patients receiving different classes of drugs for treatment of HF

* ACE inhibitors (duration, dosage, proportion of patients receiving: \<50% of target dose, 50-100% of target dose, ≥100% of target dose); * B-blockers (duration, dosage, proportion of patients receiving: \<50% of target dose, 50-100% of target dose, ≥100% of target dose); * ARBs (duration, dosage, proportion of patients receiving: \<50% of target dose, 50 100% of target dose, ≥100% of target dose); * MRAs (duration, dosage, proportion of patients receiving: \<50% of target dose, 50 100% of target dose, ≥100% of target dose); * ARNI (duration, dosage, proportion of patients receiving: \<50% of target dose, 50 100% of target dose, ≥100% of target dose); At baseline of this study

Time frame: Baseline

Proportion of patients with HFrEF with implantable devices

* Implantable cardioverter-defibrillator (ICD) (recommended; implanted); * Cardiac resynchronisation therapy (CRT) (recommended; implanted); * CRT with defibrillation (CRT-D) (recommended; implanted); * Left ventricular assist device (LVAD); At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with cardiac surgery and endovascular procedures

* Revascularisation with PCI; * Revascularisation with CABG; * Valvular surgery; * Heart transplantation; At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving dual disease-modifying therapy

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving triple disease-modifying therapy

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) receiving quadruple disease-modifying therapy

At baseline of this study

Time frame: Baseline

Proportion of patients (in total sample and subgroups of patients with HFrEF, HFmEF and HFpEF) with CHF receiving different classes of glucose lowering drugs and their combinations for T2DM treatment

* Modification of diet and lifestyle only; * Metformin; * Sulfonylureas; * Inhibitors of dipeptidyl peptidase-4 (iDPP4); * iSGLT2; * Glucagon-like peptide-1 receptor agonists (GLP1 RA); * Acarbose; * Insulins. At baseline of this study

Time frame: Baseline